ALIMERA SCIENCES INC
ALIM evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- iluvien (Approved)
What it means
What to watch
Prepared research question
What matters most for ALIM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 2 FDA decisions for ALIMERA SCIENCES INC.
Similar companies
Run ALIMERA SCIENCES INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ALIMERA SCIENCES INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is ALIMERA SCIENCES INC's lead drug candidate?
ALIMERA SCIENCES INC's most advanced tracked candidate is iluvien (Approved) for Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
What therapeutic areas does ALIMERA SCIENCES INC focus on?
ALIMERA SCIENCES INC develops therapies across Ophthalmology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.